These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 10220597)

  • 21. Economics and Cost-Effectiveness in Evaluating the Value of Cardiovascular Therapies. Proceedings of a symposium. St. Petersburg, Florida, USA. April 17-20, 1997.
    Am Heart J; 1999 May; 137(5):S35-144. PubMed ID: 10366362
    [No Abstract]   [Full Text] [Related]  

  • 22. Economics and cost-effectiveness in evaluating the value of cardiovascular therapies. Use of abciximab: comparative economic data.
    Mark DB; Simons TA
    Am Heart J; 1999 May; 137(5):S123-5. PubMed ID: 10220613
    [No Abstract]   [Full Text] [Related]  

  • 23. Current trends in cardiovascular therapy.
    Palmaz JC
    J Cardiovasc Surg (Torino); 2009 Feb; 50(1):3-6. PubMed ID: 19179985
    [No Abstract]   [Full Text] [Related]  

  • 24. What future does the pharmaceutical industry have in the cardiovascular world?
    Braunwald E
    Eur Heart J; 2013 Apr; 34(13):943-4. PubMed ID: 23546415
    [No Abstract]   [Full Text] [Related]  

  • 25. Economics and cost-effectiveness in evaluating the value of cardiovascular therapies. What constitutes a useful economic study? The health systems perspective.
    Lee TH
    Am Heart J; 1999 May; 137(5):S67-70. PubMed ID: 10220600
    [No Abstract]   [Full Text] [Related]  

  • 26. Evaluating the costs and effectiveness of cardiovascular therapies: who cares about economic analyses?
    Califf RM
    Stat Med; 2002 Oct; 21(19):2889-97. PubMed ID: 12325105
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Merck Serono targets convenient, affordable medicines for patients at risk.
    Cardiovasc J Afr; 2009; 20(1):77. PubMed ID: 19287822
    [No Abstract]   [Full Text] [Related]  

  • 28. A position paper on drug-pricing strategies for prescription pharmaceuticals in Canada. Canadian Cardiovascular Society.
    Can J Cardiol; 1997 Jan; 13(1):33-45. PubMed ID: 9039063
    [No Abstract]   [Full Text] [Related]  

  • 29. The Canadian Cardiovascular Society and reference-based drug pricing.
    Olley PM; McLaughlin PR
    Can J Cardiol; 1998 May; 14(5):669-70. PubMed ID: 9627521
    [No Abstract]   [Full Text] [Related]  

  • 30. Incorporation of economic evidence in the Dutch guideline 'cardiovascular risk management'.
    Tan SS; Rutten FF; Hakkaart-van Roijen L
    J Eval Clin Pract; 2011 Dec; 17(6):1094-101. PubMed ID: 21040249
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [The elderly cardiovascular patient in general practice. Health care costs--drugs--economic feasibility].
    Schmidt K
    Fortschr Med; 1996 Mar; 114(7):43-4. PubMed ID: 8900969
    [No Abstract]   [Full Text] [Related]  

  • 32. The Imminent Demise of Cardiovascular Drug Development.
    Packer M
    JAMA Cardiol; 2017 Dec; 2(12):1293-1294. PubMed ID: 29117286
    [No Abstract]   [Full Text] [Related]  

  • 33. The change of cost: reference-based pricing and the statins.
    Thomas M
    Can J Cardiol; 1999 May; 15(5):535-8. PubMed ID: 10350662
    [No Abstract]   [Full Text] [Related]  

  • 34. Will personalized drugs for cardiovascular disease become an option? - Defining 'Evidence-based personalized medicine' for its implementation and future use.
    de Denus S; Dubé MP; Tardif JC
    Expert Opin Pharmacother; 2015; 16(17):2549-52. PubMed ID: 26371722
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Predictors of annual pharmaceutical costs in Australia for community-based individuals with, or at risk of, cardiovascular disease: analysis of Australian data from the REACH registry.
    Ademi Z; Liew D; Hollingsworth B; Steg PG; Bhatt DL; Reid CM;
    Am J Cardiovasc Drugs; 2010; 10(2):85-94. PubMed ID: 20334445
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Would a national pharmaceutical strategy be bad for the cardiovascular health of Canadians?
    Tu JV
    Can J Cardiol; 2007 Jul; 23(9):719-20. PubMed ID: 17622394
    [No Abstract]   [Full Text] [Related]  

  • 37. RE: M Thomas. The change of cost: reference-based pricing and the statins. 1999;15:535-8.
    McNee W
    Can J Cardiol; 1999 Nov; 15(11):1287. PubMed ID: 10841625
    [No Abstract]   [Full Text] [Related]  

  • 38. Medical economics and the assessment of value in cardiovascular medicine: Part I.
    Mark DB; Hlatky MA
    Circulation; 2002 Jul; 106(4):516-20. PubMed ID: 12135955
    [No Abstract]   [Full Text] [Related]  

  • 39. [Cardiovascular pharmacotherapy in old age: How beneficial is it? What does it cost?].
    Gysling E
    Praxis (Bern 1994); 1995 Oct; 84(44):1248-51. PubMed ID: 7491446
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Drug treatment and cost of cardiovascular disease in Australia.
    Ademi Z; Liew D; Chew D; Conner G; Shiel L; Nelson M; Soman A; Steg G; Bhatt DL; Reid C;
    Cardiovasc Ther; 2009; 27(3):164-72. PubMed ID: 19689615
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.